Holen Sie sich die Stockscreener-App
83.55
0.43%
0.06
Schlusskurs vom Vortag:
$83.49
Offen:
$83.3
24-Stunden-Volumen:
190.51K
Relative Volume:
0.56
Marktkapitalisierung:
$1.55B
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-9.1112
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
+13.28%
1M Leistung:
+3.61%
6M Leistung:
+56.67%
1J Leistung:
+103.12%
1-Tages-Spanne:
$81.72
$84.73
1-Wochen-Bereich:
$73.50
$84.73
52-Wochen-Spanne:
$33.01
$86.93
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
83.74 | 1.55B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.92 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.54 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
668.35 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.79 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.21 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Should You Invest in Nasdaq Inc (NDAQ) Now? - The News Heater
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 5.8%Should You Buy? - MarketBeat
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Praxis Precision Medicines to Present at Two February Investor Conferences - The Manila Times
CNS Drug Developer Praxis Lines Up Exclusive Investor Access at Guggenheim & Oppenheimer Events - StockTitan
China Universal Asset Management Co. Ltd. Makes New Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Learn to Evaluate (PRAX) using the Charts - Stock Traders Daily
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Praxis Precision Medicines (PRAX) Stock Price, News & Analysis - MarketBeat
Jefferies maintains Praxis stock with $305 target, bullish on catalysts - MSN
Noteworthy Wednesday Option Activity: PRAX, ORCL, SOC - Nasdaq
Jefferies maintains Praxis stock with $305 target, bullish on catalysts By Investing.com - Investing.com South Africa
Praxis Precision Medicines (NASDAQ:PRAX) Shares Up 8.5% Following Analyst Upgrade - Defense World
Truist Financial Issues Positive Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock Price - Defense World
Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts - Benzinga
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 8.5% Following Analyst Upgrade - MarketBeat
Truist raises Praxis stock target to $175 on study optimism - MSN
Truist raises Praxis stock target to $175 on study optimism By Investing.com - Investing.com Australia
Praxis Precision Medicines (NASDAQ:PRAX) Given New $175.00 Price Target at Truist Financial - MarketBeat
Ellsworth Advisors LLC Takes $627,000 Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Short Interest Update - MarketBeat
Trend Tracker for (PRAX) - Stock Traders Daily
Assenagon Asset Management S.A. Has $43.03 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines Unveils Ambitious 2025 Strategy: 4 Pivotal Trial Readouts, $470M Cash Runway - StockTitan
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities - The Bakersfield Californian
Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 8.9%Here's Why - MarketBeat
(PRAX) Trading Report - Stock Traders Daily
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference - The Manila Times
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Long Term Trading Analysis for (PRAX) - Stock Traders Daily
Geode Capital Management LLC Has $22.95 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by Barclays PLC - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Acquired by Barclays PLC - MarketBeat
Praxis Precision Medicines: Multiple Potential Drivers (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines Inc (NASDAQ: PRAX) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Franklin Resources Inc. Grows Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
State Street Corp Has $45.44 Million Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $913,000 Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
(PRAX) Technical Data - Stock Traders Daily
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine - The Bakersfield Californian
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome - GlobeNewswire
Praxis Precision Medicines Secures Key FDA Designation for Promising Epilepsy Drug Relutrigine - StockTitan
Praxis Precision Medicines (NASDAQ:PRAX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Wellington Management Group LLP Buys 168,394 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World
BNP Paribas Financial Markets Has $548,000 Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
BNP Paribas Financial Markets Purchases 7,496 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation - Simply Wall St
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):